We are the first to test a JAK1/2 inhibitor in combination with a SOD mimetic in HGPS fibroblasts to target the mitochondrial dysfunction and reduce chronic inflammation in HGPS. The gene discussed is SOD1; the disease is Hutchinson-Gilford progeria syndrome.